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Abstract: The relatively low survival rate in patients with advanced-stage carcinoma 
ovaries requires early detection to improve treatment outcomes. The method currently 
used to determine the administration of neoadjuvant chemotherapy is ascites cytology 
and laparoscopic. This study aims to find a non-invasive technique in determining 
preoperative Neoadjuvant Chemotherapy administration, and that method can use as 
a predictor of advanced epithelial ovarian carcinoma. The benefit of this study is to 
help clinicians consider administering neoadjuvant chemotherapy with a Risk Of 
Malignancy Index 4 score. An analytical observational study with a retrospective cross-
sectional type study with samples of all patients from January 2016 to January 2020 
diagnosed at the dr. Saiful Anwar Hospital in Malang indonesia. The number of initial 
samples of this study is 106 samples. Between the results of the Risk Of Malignancy 
Index 4 score and the histopathological results, it finds that the p-value was less than 
0.05 (p<0.05) indicates that the Risk Of Malignancy Index 4 score is very good for 
predicting advanced epithelial ovarian carcinoma. With a sensitivity of 86,2%, 
specificity of 87,5%, the cut of value Risk Of Malignancy Index  4 to be a predictor of 
advanced ovarian carcinoma is 2982. This study indicates that the Risk Of Malignancy 
Index 4 score is excellent for predicting the stage of Epithelial Ovarian Carcinoma. 
This cut-off value can reference preoperative neoadjuvant therapy to avoid morbidity 
and mortality due to the high risk of surgery. 
Keywords: Risk of malignancy index; ovarian carcinoma; advanced stage; diagnostic 
test; neoadjuvant chemotherapy. 
 
INTRODUCTION 
 Worldwide, ovarian carcinoma has the highest mortality rate of all gynecologic 
malignancies (Mutch and Prat 2014). According to WHO/IARC (International Agency 
for Research on Cancer), the incidence of ovarian carcinoma in Indonesia ranks 
second after cervical carcinoma with an incidence rate of 9664 cases in 2008 (Loomis, 
Huang, and Chen 2014). The high morbidity and mortality rate is related to the 
complications found in the operation of patients with advanced ovarian carcinoma who 
underwent surgery without neoadjuvant chemotherapy, including adhesions, organ 
injury, and bleeding (Worley Jr et al. 2013). 
         The standard primary therapy for patients with advanced ovarian carcinoma is 
primary debulking surgery followed by adjuvant chemotherapy with Carboplatin and 
Paclitaxel (Pignata et al., 2011). Debulking considers optimal if the residue left is 1cm 
in size. The increasing morbidity and mortality of debulking performed in the context 
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of proving an ovarian carcinoma at an early stage is a dilemma. Therefore, 
neoadjuvant chemotherapy use for primary ovarian carcinoma, which predicts to be 
less likely to achieve optimal cytoreduction if surgery performs (Fauziah and Andrijono, 
2007). Patients with poor performance status, who are at high risk for morbidity and 
mortality if cytoreduction surgery performs, can also be given multiple cycles and 
standard chemotherapy before surgery so that subsequent cytoreduction surgery will 
be safer (Chan et al., 2003).  
 Neoadjuvant Chemotherapy (NACT) in advanced epithelial ovarian cancer is 
the last concept to discuss to treat progressive disease. Neoadjuvant implies the 
administration of chemotherapy before cytoreductive surgery. So far, the procedure 
for determining the administration of NACT still bases on two methods, namely ascites 
cytology and laparoscopy. And the requirement for giving NACT is to attach the results 
of the Anatomical Pathology laboratory (Baransi et al. 2020). 
 Ankara Maternity Hospital Turkey has conducted a study to assess neoadjuvant 
chemotherapy as an alternative to surgery in the initial treatment of bulky ovarian 
tumors. Neoadjuvant chemotherapy followed by debulking laparotomy has not been 
shown to worsen the prognosis but instead reduces aggressive surgery and improves 
the quality of life (Lu et al. 2001). 
 The multiparametric Risk of Malignancy Index (RMI) score can be a valuable 
tool in predicting ovarian malignancy in areas with limited resources. The Risk of 
Malignancy Index (RMI), which considers serum CA-125 levels, menopausal status, 
and ultrasound findings in predicting malignant pelvic masses, is widely used in 
developed countries (Aziz and Najmi 2015). Yamamoto in 2009, who confirmed that 
RMI 4 is more reliable than RMI 1, RMI 2, and RMI 3 (Yamamoto et al. 2014). 
However, there are no studies that indicate early-stage and advanced-stage ovarian 
carcinoma from an RMI 4. Previously, many researchers had developed this RMI but 
were only limited to distinguishing benign and malignant adnexal tumors (Campos et 
al. 2016) (Akker van den et al. 2016) (Ulusoy et al. 2007) (Clarke et al. 2009). This 
research is the first study to develop the RMI score as a predictor of advanced stage. 
No previous studies are looking for non-invasive methods as a consideration for giving 
NACT. The purpose of this study is to find a non-invasive way to assist clinicians in 
considering the administration of NACT with a method that is simple, fast, and does 
not require high costs. 
 
MATERIALS AND METHOD 
 This study uses an analytical observational research design type cross-
sectional study; in this study, the researchers tried to find the relationship between 
variables, namely by analyzing the data collected—this study conduct in April 2021. 
The sample population is all populations suffering from ovarian malignancy in the 
oncology department of the Department of Obstetrics Gynecology dr. Saiful Anwar 
Hospital Malang Indonesia. The research sample was taken with a retrospective study, 
data collection from the medical record of patients suffering from ovarian malignancies 
for the last five years, from January 2016 until January 2020. Based on data obtained 
from 5 years, 253 patients had ovarian carcinoma after all the medical records were 
searched; based on the inclusion and exclusion criteria, 106 samples get. 
 Samples also take from the Anatomical Pathology Laboratory of dr. Saiful 
Anwar Hospital Malang. This research was approved by the Ethics committee of 
general hospital dr. Saiful Anwar Malang, with regards to the protection of human 
rights and welfare in medical research, has carefully reviewed the research protocol 
entitled with the number of registration 400/260/K.3/302 /2020. After all medical 
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records of patients suffering from ovarian carcinoma were collected, a data collection 
sheet containing the necessary medical record data such as age, patient 
demographics, menopausal status, CA 125 levels, ultrasound results, and 
histopathology results. 
 In this study, data analysis techniques were used to measure the Risk 
Malignancy Index 4 (RMI4) accuracy, assessed by positive predictive value, negative 
predictive value, sensitivity, specificity, and accuracy value. The ROC curve uses to 
determine the cut-off value of RMI4 with histopathological appearance according to 
advanced-stage ovarian carcinoma. This statistical analysis uses SPSS version 25.0, 
To get all these accuracy values using a statistical test of the ROC curve and 
characteristic data using chi-square. 
  
RESULTS AND DISCUSSION 
 Based on the polyclinic oncology and anatomic pathology laboratory data for 
the previous five years there is 253 patients had ovarian carcinoma. After all the 
medical records were searched, based on the inclusion and exclusion criteria, 106 
samples obtain. Then performed staging by oncology clinician, obstetrics and 
gynecology department of dr. Saiful Anwar Hospital obtains as many as 48 samples 
suffering from early stages and 58 samples suffering from advanced stages. The 
characteristics of this research sample can see in tables 1 and 2. 
Subject Characteristics 
 Based on the table regarding the study sample characteristics, it shows that of 
the 48 early-stage patients, the majority are 41-50 years old, and the majority of 58 
patients are 51-60 years old. Using the Chi-Square t-test, obtained a p-value of 0.008 
(p<0.05), indicating a statistically significant age difference. This result suggests that 
the age group of patients with advanced-stage Epithelial Ovarian Carcinoma is older 
than the group of patients with early Epithelial Ovarian Carcinoma. 
 Based on the characteristics of education, it was shown that in the early-stage 
Epithelial Ovarian Carcinoma patient group, most of the patients had high school 
education, namely 19 (39.6%) and in the group of advanced Epithelial Ovarian 
Carcinoma patients with junior high school education, 24 (41.4%) patients. Using the 
Chi-Square test, a p-value of 0.521 (p>0.05) obtains, which explains no difference in 
educational characteristics between the two groups of patients. Likewise, the 
characteristics of marital status, parity, family planning, BMI, Family History of Tumors, 
and menstrual cycles in both groups were relatively the same (p>0.05). 
 Based on the characteristics of ascites and papillae, the p-value was less than 
0.05 (p<0.05), proving that there are differences in the characteristics of the two 
groups of patients. Patients with advanced epithelial ovarian carcinoma have more 
ascites and papillae than patients with early-stage epithelial ovarian carcinoma. 
 Based on the characteristics of the septa and tumor size, a p-value of > 0.005 
obtains, which means that there was no significant difference in patients with early and 
advanced epithelial ovarian carcinoma compared to the characteristics of the 
ultrasound septa and tumor size. 
 Based on the characteristics of the septa and tumor size, a p-value of > 0.005 
obtains, which means that there was no significant difference in patients with early and 
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Table 1. Sample Demographic Characteristics Table 
 
Characteristic 




(n = 48) 
Advance 
 (n = 58) 
Age    
20 - 30 years 4 (8.3%) 1 (1.7%) 0.008** 
31 - 40 years 7 (14.6%) 6 (10.3%)  
41 - 50 years 25 (52.1%) 17 (29.3%)  
51 - 60 years 9 (18.8%) 26 (44.8%)  
61 - 70 years 1 (2.1%) 7 (12.1%)  
71 - 80 years 2 (4.2%) 1 (1.7%)   
Education    
Elementary 
school 13 (27.1%) 13 (22.4%) 0.521 
Junior high school 15 (31.3%) 24 (41.4%)  
Senior high 
school 19 (39.6%) 21 (36.2%)  
Univeristy 1 (2.1%) 0 (0%)   
Married Status   
Single 5 (10.4%) 4 (6.9%) 0.286 
Married once 37 (77.1%) 40 (69%)  
Married more 
than once  6 (12.5%) 14 (24.1%)   
Parity    
Nuliparous 17 (35.4%) 15 (25.9%) 0.286 
Multiparous 31 (64.6%) 43 (74.1%)   
Contraception    
Not Yet 9 (18.8%) 10 (17.2%) 0.840 
Already 39 (81.3%) 48 (82.8%)   
BMI    
Underweight 18 (37.5%) 33 (56.9%) 0.110 
Normal 23 (47.9%) 21 (36.2%)  
Overweight 7 (14.6%) 4 (6.9%)   
Family history of Gynecologic 
Cancer  
Denied 46 (95.8%) 55 (94.8%) 0.808 
Be Found 2 (4.2%) 3 (5.2%)   
NACT History    
Not Yet 42 (87.5%) 31 (53.4%) 0.000** 
Already 6 (12.5%) 27 (46.6%)   
Menstrual cycle   
Regular 44 (91.7%) 56 (96.6%) 0.279 
Not Regular 4 (8.3%) 2 (3.4%)   
*Chi-square test results 
**p-value have significance effect with marks 
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Table 2. Characteristics Table of Ultrasonographic Variables 
 
Variabel USG 




(n = 48) 
Advance 
(n = 58) 
Asites    
Not Found 36 (75%) 18 (31%) 0.000** 
Found 12 (25%) 40 (69%)   
Papil    
Not Found 33 (68.8%) 26 (44.8%) 0.014** 
Found 15 (31.3%) 32 (55.2%)   
Septa    
Not Found 18 (37.5%) 24 (41.4%) 0.684 
Found 30 (62.5%) 34 (58.6%)   
Solid Part    
Not Found 21 (43.8%) 11 (19%) 0.006** 
Found 27 (56.3%) 47 (81%)   
Metastasis Intra Abdomen   
Not Found 48 (100%) 51 (87.9%) 0.013** 
Found 0 (0%) 7 (12.1%)    
Tumor Size   
< 7 0 (0%) 2 (3.4%) 0.194 
>= 7 48 (100%) 56 (96.6%)   
*Chi-square test results 
**p-value have significance effect with marks 
 
Curve ROC RMI 4 
 Determination of Cut Off Value RMI4 to predict Epithelial Ovarian Carcinoma 
Advanced stage can be measured using the ROC curve. the ROC curve of the RMI4 
score can see in figure 1. 
 
Figure 1. Determination of the RMI4 Cut Off Value is Measured Using  
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Table 3. Area of the ROC Curve, P-Value , CI of Score RMI4 
 
Variable Area p-value 95% CI 
RMI 4 0.948 0.000 0.912 - 0.984 
 
 Based on table 3 above, the predicted results of the RMI4 score in predicting 
advanced-stage Epithelial Ovarian Carcinoma obtained a p-value of less than 0.05 
(p<0.05) with an area of 0.948 and 95% CI of 0.912 - 0.984. A P-value less than 0.05 




Figure 2. Sensitivity and Specificity Plot from Cut-off Value RMI4 Skor Score,  
the Red Line Shows the Intersection of the Sensitivity and Specificity Values of RMI4 
 
 Based on Figure 2, a plot between the sensitivity and specificity values of the 
RMI 4 score shows. As explained in the figure, it shows that there is an intersection of 
the sensitivity and specificity values. The intersection point obtains from the 
combination of the highest sensitivity and specificity values. The sensitivity and 
specificity values in the appendix show that the highest combination of sensitivity and 
specificity values locates at the RMI 4 point of 2982. At that point, the sensitivity value 
is 86,2 %, and specificity is 87,5%. Thus, the cut-off value of the RMI4 score to 
determine advanced epithelial ovarian carcinoma is 2982. 
         The accuracy of RMI 4 in predicting the stage of ovarian epithelial carcinoma 
can be done by calculating the Positive Predictive Value (PPV), Negative Predictive 
Value (NPV), and Accuracy value. These coefficients calculate by comparing the 
predicted results of RMI 4 with the results of histopathological examination. In this 
study, the accuracy level was measured by comparing 4 RMI 4 cut-off points. The 
results of calculating the RMI 4 accuracy level in predicting advanced-stage epithelial 
ovarian carcinoma at four cut-off points can see in table 4. 
 The four cut-off points show that RMI 4 with a cut-off point of 2982 has the 
highest PPV, NPV, and accuracy values. This test proved that RMI 4 of 2982 was 
more appropriate to use as a cut-off point predictor of advanced epithelial ovarian 
carcinoma. 
RMI 4 Accuracy Level as a Predictor of Advanced Epithelial Ovarian Carcinoma 
         The accuracy of RMI4 in predicting the stage of Epithelial Ovarian Carcinoma 
can be done by calculating the Positive Predictive Value (PPV), Negative Predictive 
Value (NPV), and the accuracy value. The PPV, NPV, and accuracy value calculate 
by comparing the predicted results of RMI4 with histopathological examination results. 
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The results of calculating the RMI4 accuracy level in predicting the stage of Epithelial 
Ovarian Carcinoma can see in table 5. 
 
Tabel 4. Comparison of Sensitivity, Specificity, NPV, PPV, and Accuracy Values of 
the Four Scores that are Close to the Ideal Cut-off Value 
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 Based on the analysis table using the contingency coefficient of the relationship 
between the results of RMI 4 and histopathological results, the positive predictive 
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value (PPV) was 89.2%, and the negative predictive value was 84.0%. And the 
accuracy value is 86,8%. 
         The International Agency for Research on Cancer states that the incidence of 
ovarian carcinoma in Indonesia ranks second most after cervical carcinoma with an 
incidence rate of 9664 cases in 2008, with the age group suffering from ovarian 
carcinoma the most being the age group 41 to 50 years, which is 62.7%. And at least 
31 to 40 years, which is as much as 10.8% (Loomis, Huang, and Chen 2014).  
         The age of women diagnosed with early-stage ovarian carcinoma is mainly in 
the age group of 41-50 years, and from 58 women who included in the advanced 
stage, the most are in the age group of 51-60 years (Table 1). Statistical analysis 
obtained a p-value of 0.008 where the p-value is smaller than 0.05, which indicates a 
significant difference and indicates that the age group of women with advanced-stage 
ovarian carcinoma is older than the group of women with early stage. The results 
obtained in this study are in line with a retrospective study conducted in Wales, United 
Kingdom, in which 247 women with ovarian carcinoma were at an average age of 
58.09 (Abdulrahman Jr, McKnight, and Singh 2014). Meanwhile, based on the 
Holland-Frei Cancer Medicine 6th edition, the mean age of patients diagnosed with 
ovarian epithelial carcinoma is between the ages of 60 and 65 years (Berek and Bast 
Jr 2003). The mean age of women with ovarian epithelial carcinoma in this study is 
also in line with research conducted at the RSSA gynecology poly oncology in 2019, 
54.2 ± 10.3 (Nurseta et al. 2020).  
         This study revealed that in women diagnosed with ovarian carcinoma in January 
2016–January 2020, the highest proportion find in the multiparous patient group, 
namely 31 (64.6%) in the early stage and 43 (74.1%) in the advanced stage (Table 1). 
It showed no difference in parity characteristics with the incidence of ovarian 
carcinoma (p=0.286). The results of this study are not in line with some case controls 
showing that multiparous women have a 30-60% lower risk of ovarian cancer. 
Increased parity is associated with a reduced risk of ovarian malignancy (Montes et 
al., 2012). It is also not by the results of studies that say pregnancy reduces the risk 
of ovarian tumor malignancy by 19% (McGuire 2016). 
         This study did not show a significant relationship between contraceptive use and 
ovarian tumor malignancy. This result could be due to the distribution of contraceptive 
users in a small sample. The number of women in this study mainly was never used 
contraception, namely 87 (82.1%) based on table 1. The use of oral contraceptives for 
more than three years is known to reduce the risk of ovarian tumor malignancy 
compared to women who do not use or only use it in the short term. Each of the 
contraceptive methods examined reduced the risk of ovarian cancer compared with 
the use of no artificial contraception (Ness et al., 2011). 
         The high morbidity and mortality rate is related to the complications found in the 
operation of patients with advanced ovarian carcinoma who underwent surgery without 
neoadjuvant chemotherapy, including adhesions, organ injury, and bleeding. The 
incidence of vascular injury reports being 0.04% to 0.5%. Gastrointestinal injuries 
description in 0.13%, including small intestine (55.8%), large intestine (38.6%), and 
gastric (3.9%) (Worley Jr et al. 2013). 
         This study proves that RMI 4 can use as a predictor of advanced epithelial 
ovarian carcinoma with a p-value <0.05 and a positive predictive value (PPV) of 
89.3%, and a negative predictive value of 84.0%. The best cut-off point value as a 
predictor of advanced epithelial ovarian carcinoma find at 2982, with a sensitivity of 
82%, specificity 87,5%, positive predictive value (PPV) of 89.3%, and negative 
predictive value (NPV) of 84% (Table 4). The study conducted by Tingulstad modified 
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the RMI and defined RMI 4, and they observed that at the cut-off level of 450, the 
sensitivity and specificity were 71% and 92% (Fainbaum and Batista 2017). This level 
of accuracy is in line with a study involving 548 female patients; they calculated an 
RMI with a cut-off point of 200, where there were sensitivity, specificity, PPV, and NPV 
of 81%, 85%, 48%, and 96%, respectively (Campos et al. 2016). In another study, 
which used 100 female patients with ovarian carcinoma with a cut-off point of 450, the 
sensitivity, specificity, PPV, and NPV were 90%, 89%, 96%, and 78%, respectively 
(Ulusoy et al. 2007).  
 In the study group, Aktürk stated no statistically significant differences in 
identifying different malignancy risk indices between RMI 1, RMI 2, RMI 3, and RMI 4 
(Aktürk et al. 2011). This study is also in line with a survey conducted by Milan Terzic. 
He said that the efficacy of RMI has been validated in many studies and has proven 
to be a simple, low-cost, and effective tool for triage management of ovarian carcinoma 
(Terzic et al., 2013). The sensitivity of RMI 4 indicates that it can label malignant 
tumors in high-risk cases, while its specificity demonstrated that it could label benign 
tumors as low-risk cases. It was the best result when all the parameters examined 
sensitivity, specificity, PPV, and NPV were high (Clarke et al., 2009).  
 The advantage of this study is that the results can use as a new regulation in 
an integrated oncology gynecology referral hospital in consideration of giving NACT 
with the first non-invasive method. The main limitation of this study is the retrospective 
design. A future retrospective study is likely to have fewer potential data sources and 
confounders. The medical record completeness factor also affects the number of 
samples obtained because most of the required data is missing. 
 
CONCLUSION 
In conclusion, the results of this study indicate that the RMI4 score is very good 
to use in predicting the stage of Epithelial Ovarian Carcinoma. The best cut-off point 
RMI 4 can be used as a reference limit to determine advanced stage Epithelial Ovarian 
Carcinoma is 2982. Neoadjuvant Chemotherapy (NACT) in advanced epithelial 
ovarian cancer is the last concept that needs to discuss to treat progressive disease. 
Neoadjuvant implies the administration of chemotherapy before cytoreductive surgery. 
It hopes that this cut-off value can be a reference for preoperative neoadjuvant therapy 
to avoid morbidity and mortality due to the high risk of surgery. And this non-invasive 
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